ABSTRACT BACKGROUND: There are 2 mainstays of therapy for malignant or aggressive brain tumors that are effective in controlling growth: systemic treatments such as immunotherapy and chemotherapy and radiation including brachytherapy. Prior versions of brain brachytherapy have proven challenging to use due to adverse effects, resulting in limited application of this therapy. The most recent development in brain brachytherapy is a tile-based radioactive device, GammaTile ® , that is implanted at the time of tumor removal. GammaTile is FDA-approved for malignant brain tumors as well as recurrent brain tumors and addresses all the nuances of prior versions. This literature review provides neuroscience nurses with a working understanding of tile-based brain brachytherapy. METHODS: Searches were conducted across multiple medical databases including PubMed, CINAHL, and EBSCO, using combinations of keywords related to brachytherapy, GammaTile, and brain tumors to identify relevant background and descriptive literature, and using combinations of keywords, nursing care, brachytherapy, brain, head, and malignancies, to identify relevant nursing care literature. RESULTS: Fifteen recently published articles were deemed relevant to provide neuroscience nurses with a working knowledge of tile-based brain brachytherapy. Literature on the nursing care of patients receiving tile-based brain brachytherapy is scarce, and only 2 articles published within the past 40 years specific to nursing care of patients receiving brain brachytherapy were discoverable. CONCLUSION: As the number of GammaTile cases and centers across the country continue to mount, neuroscience nurses need to have a working knowledge of this type of tile-based brain brachytherapy. There are significant differences in the care of patients after implantation of tile-based radiation therapy like GammaTile compared with prior brachytherapy products. These differences have implications for nurse and patient safety and patient/family education.
Tammy L. Tyree (Fri,) studied this question.